---
created: 2025-04-13
updated: 2025-04-13T10:53
id: zh`_DR`L68
specialty: pharmaco
specialty_id: 489
tags:
  - source/ak-original-decks::step-1::lolnotacop::drugs
  - "source/ak-step1-v11:": 
  - theme/firstaid::02-immunology::04-immunosuppressants::04-therapeutic-antibodies
  - "source/ak-step1-v11:": 
  - theme/firstaid::02-immunology::04-immunosuppressants::04-therapeutic-antibodies::*basics
  - "source/ak-step1-v11:": 
  - theme/firstaid::10-hematology-oncology::05-pharm::21-cetuximab-panitumumab
  - "source/ak-step1-v11:": 
  - theme/firstaid::10-hematology-oncology::05-pharm::23-rituximab
  - "source/ak-step1-v11:": 
  - theme/firstaid::10-hematology-oncology::05-pharm::23-rituximab::*basics
  - "source/ak-step1-v11:": 
  - theme/nbme::29
  - "source/ak-step1-v11:": 
  - source/ome-banner::basic-science::07-immunology
  - "source/ak-step1-v11:": 
  - theme/physeo::09-pharm::09-musculoskeletal::09-tnf-alpha-inhibitors
  - "source/ak-step1-v11:": 
  - theme/pixorize::02-biochem::22-onc-drugs::02-rituximab
  - "source/ak-step1-v11:": 
  - theme/pixorize::02-biochem::22-onc-drugs::03-cetuximab,-panitumumab
  - "source/ak-step1-v11:": 
  - theme/pixorize::03-pharm::11-oncology::cetuximab,-panitumumab
  - "source/ak-step1-v11:": 
  - theme/pixorize::03-pharm::11-oncology::rituximab
  - "source/ak-step1-v11:": 
  - theme/pixorize::03-pharm::12-msk::tnf-inhibitors-(infliximab,-adalimumab.-certolizumab,-golimumab)
  - "source/ak-step1-v11:": 
  - theme/sketchypharm::08-antineoplastics::03-kinase-inhibitors-&-monoclonal-antibodies::02-rituximab,-cetuximab,-bevacizumab,-alemtuzumab,-trastuzumab
  - "source/ak-step1-v11:": 
  - theme/uworld::1000-9999::7000-7999::7656
  - "source/ak-step1-v11:": 
  - theme/uworld::10000-99999::20000-20999::20698
type: flashcard
---

# Question
Chimeric monoclonal antibodies (eg, infliximab, rituximab) can cause a(n) **serum sickness** within **7-14** days of administration == self-limited fever, arthralgia, and urticarial rash ~ highly inflammatory toxins C3a and C5a  * Bonus: What's the immunologic mechanism explained?

---

# Answer
type III HSR (immune complexes deposit in skin, joints or vessels == activate classical complement == neutrophils from the mononuclear phagocyte system == vasculitis and fibrinoid necrosis)    1-2w post-exposure to antitoxins (eg, antivenom), monoclonal Ab, or vaccines (eg, rabies antigens);  Why? Time lag between antigen processing, presentation, CD4 T-lymphocyte activation, and T-cell-mediated B-cell activation/differentiation